GlassScriptPhysician profile
Manilal B Mehta
NPI 1124024104
$583.37
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $32.20 · 2021: $171 · 2022: $42.80.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $406.95 | 2019-2021 | |
| Boston Scientific Corporation | $45.50 | 2019 | |
| Pfizer INC. | $32.46 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.46 | 2022 | |
| Myovant Sciences INC. | $22.81 | 2021 | |
| Abbvie INC. | $19.34 | 2022 | |
| Mission Pharmacal Company | $16.80 | 2019 | |
| Janssen Biotech, INC. | $16.05 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manilal Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.